Trial Profile

Phase II safety and efficacy study of alectinib in poor performance status patients with ALK positive, advanced NSCLC

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 16 Mar 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Alectinib (Primary)
Indications Adenocarcinoma; Non-small cell lung cancer
Focus Therapeutic Use
Acronyms LOGIK1401

Most Recent Events

15 Mar 2021 Status changed from active, no longer recruiting to completed.
18 Oct 2017 Results assessing efficacy of alectinib for patients with Alk rearrangement positive non-small cell lung cancer and a poor performance status presented at the 18th World Conference on Lung Cancer
23 Feb 2017 Results published in the Journal of Thoracic Oncology

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com